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Background: Selective serotonin reuptake inhibitors (SSRI) decrease platelet-function, which suggests that SSRI use
may increase the risk of post-surgical bleeding. Few studies have investigated this potential association.
Methods: We conducted a population-based study of the risk of re-operation due to post-surgical bleeding within
two weeks of primary surgery among Danish women with primary breast cancer. Patients were categorised
according to their use of SSRI: never users, current users (SSRI prescription within 30 days of initial breast cancer
surgery), and former users (SSRI prescription more than 30 days before initial breast cancer surgery). We calculated
the risk of re-operation due to post-surgical bleeding within 14 days of initial surgery, and the relative risk (RR) of
re-operation comparing SSRI users with never users of SSRI adjusting for potential confounders.
Results: 389 of 14,464 women (2.7%) were re-operated. 1592 (11%) had a history of SSRI use. Risk of re-operation
was 2.6% among never users, 7.0% among current SSRI users, and 2.7% among former users. Current users thus
had an increased risk of re-operation due to post-operative bleeding (adjusted relative risk = 2.3; 95% confidence
interval (CI) = 1.4, 3.9) compared with never users. There was no increased risk of re-operation associated with
former use of SSRI (RR = 0.93, 95% CI = 0.66, 1.3).
Conclusions: Current use of SSRI is associated with an increased risk of re-operation due to bleeding after surgery
for breast cancer.
Background
Selective Serotonin Reuptake Inhibitors (SSRI) decrease
platelet serotonin storage and platelet-function in
humans [1,2] and are associated with upper gastrointest-
inal bleeding [3,4]. This mechanism suggests that SSRI
use may increase the risk of post-surgical bleeding, but
data on peri-operative risk of bleeding associated with
use of SSRI are few and contradicting [5,6]. One Danish
study on coronary artery bypass surgery reported no
association between the use of SSRI and an increased
requirement for blood transfusion [5]. In contrast, a
study on orthopaedic surgery found use of SSRI
associated with a 3.7-fold increased risk of subsequent
blood transfusion [6]. Severe peri-operative bleeding,
defined as the need for blood transfusion following
breast cancer surgery, is a rare event. Even so, major
postoperative bleeding requiring re-operation occurs in
about 4% of women operated on for breast cancer [7].
The prevalence of patients using SSRI is increasing.
According to The Danish Medicines Agencys’ data,
usage has increased from 38.3 Defined Daily Doses/1000
inhabitants in 2004 to 50.3 in 2008 [8]. Additionally,
breast cancer is the most common cancer among
women, with surgery the primary treatment. Thus, an
increased risk of post-surgical bleeding associated with
SSRI use among breast cancer patients may have impor-
tant clinical implications.
* Correspondence: hts@dce.au.dk
2Department of Clinical Epidemiology, Aarhus University Hospital. Olof
Palmes Alle 43-45, Aarhus N 8200, Denmark
Gärtner et al. BMC Surgery 2010, 10:3
http://www.biomedcentral.com/1471-2482/10/3
© 2010 Gärtner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.We therefore conducted a population-based study
with prospectively collected administrative data to
examine the association between use of SSRI and re-
operation due to post-surgical bleeding in a large cohort
of Danish women undergoing breast cancer surgery.
Methods
Study population
We conducted this population-based cohort study
among residents of Northern Denmark, which has a
total population of 1.7 million inhabitants. The Danish
National Health Service provides tax-supported health-
care to all residents of the country and refunds part of
patient expenditures on a wide range of prescribed
drugs, including SSRI. A unique civil personal registra-
tion (CPR) number has been assigned to all Danish citi-
zens since 1968 by the Danish Civil Registration System.
This number encodes gender and date of birth [9], and
facilitates accurate linkage between population-based
registries.
All hospitalizations are registered to individual
patients in the National Registry of Patients, which has
covered all Danish hospitals since 1977. Data from the
National Registry of Patients on the inhabitants of
Northern Denmark have been merged into a research
database at Aarhus University [10,11]. This database
includes all non-psychiatric hospital admissions since
1977, and outpatient and emergency room data since
1994. Information is recorded in the National Registry
of Patients immediately after discharge or outpatient
visit and includes CPR number, dates of admission and
discharge, and up to 20 diagnostic codes categorized by
ICD code [12]. Using the National Registry of Patients,
we identified 14,464 female patients who had a first
diagnosis of breast cancer (ICD-10 codes C50.0-50.6,
C50.8 & C50.9) from 1 January 1996 through 31 March
2007, the time period during which we could link to
complete prescription history by the methods described
below.
Post-operative bleeding outcomes
Information on re-operation due to post-surgical bleed-
ing within 14 days of primary breast cancer-directed
surgery was retrieved from the National Registry of
Patients in accordance with the Danish Classification of
Surgical Procedures and Therapy (codes: KHWD00,
KHWE00). All breast cancer patients were treated with
either mastectomy (code KHAC) or breast-conserving
surgery (code KHAB).
SSRI prescription data
All pharmacies in Northern Denmark use computerised
accounting systems connected with the National Health
Service to record a customers’ CPR number, type and
quantity of medication dispensed (including tablet, pack-
age sizes, and number of days on prescription), and
prescription data according to the drug’s Anatomical
Therapeutic Classification (ATC) (World Health Organi-
zation Collaborating Centre for Drug Statistics Metho-
dology, 2001). Data on prescriptions for refundable
drugs are transferred electronically to the National
Health Services and to the research database at Aarhus
University, with complete coverage in the region since
1998. In Denmark, anti-depressants are available only by
prescription. We identified prescriptions for the follow-
ing SSRI anti-depressants: Fluoxetine N06AB03, citalo-
pram N06AB04, paroxetine N06AB05, sertraline
N06AB06, fluvoxamine N06AB08, and escitalopram
N06AB10. Patients were categorised according to their
use of SSRI: never users, current users (prescription of
SSRI within 30 days before initial breast cancer surgery),
and former users (prescription of SSRI more than 30
days before initial breast cancer surgery).
Data on potential confounders
To account for factors that may be associated with SSRI
anti-depressant prescription and post-surgical bleeding,
we obtained data on age at breast cancer surgery and on
preoperative use of platelet inhibitors, vitamin K antago-
nists, oral anti-coagulants, non-steroidal anti-inflammatory
drugs (NSAID) (non-aspirin NSAID, excluding selective
Cox-2 inhibitors, as these do not impair platelet function
[13]) non-SSRI anti-depressants (tri-cyclic anti-depressants
(TCA), tetracyclical anti-depressants (TeCA), and other
anti-depressants) (see Appendix for specific ATC codes).
We also obtained information on specific precedent
comorbidities including liver disease, uraemia, other can-
cers, renal diseases, autoimmune diseases, thrombocytope-
nia, and vasculitis; all of which can cause bleeding.
Statistical analyses
Follow-up began at the date of primary breast cancer
surgery and continued until fourteen days after the
operation or 1 April 2007. We analysed the data first by
tabulating contingency tables for the main study vari-
ables, from which we calculated the risk of re-operation
due to post-surgical bleeding according to use of SSRI.
We computed the crude risk difference and risk ratio
with their 95% confidence intervals associating SSRI pre-
scription with post-operative bleeding. We then strati-
fied the contingency tables according to each of the
possible confounding variables to examine the strength
of confounding. We also fitted multiple logistic regres-
sion models to the data to compute the odds ratio and
associated 95% confidence intervals that controlled for
confounding by identified confounders. Given that re-
operation for post-surgical bleeding was rare in all com-
binations of the independent variables, these adjusted
odds ratios provide an estimate of the adjusted risk
ratios (aRR). In the final model we included variables
that changed the exposure odds ratio by 10 percent
[14]. All data analyses were performed using Stata 9.0.
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Results
Characteristics of the cohort of 14,464 breast cancer
patients according to SSRI prescription are presented in
Table 1. Approximately 65% of patients were over 50
years old at initial breast cancer surgery, 60% underwent
breast-conserving surgery, and 40% underwent mastect-
omy as their primary breast cancer-directed surgery.
Slightly more women who had ever used SSRI compared
with those who had not used SSRI had also used other
prescription drugs, including NSAID, aspirin, corticoster-
oids, vitamin K antagonists and platelet inhibitors.
Women with a history of SSRI prescription had at least
one of the selected precedent comorbid diseases more
often than those who had not used SSRI (12% versus 9%).
Risk of re-operation due to post-surgical bleeding after
breast cancer surgery is presented in Table 2. In all, 389
of 14,464 women (risk = 2.7%) in the breast cancer
cohort underwent a re-operation due to post-surgical
bleeding within fourteen days following initial breast
cancer surgery. 338 of 12,872 never users of SSRI under-
went a re-operation (risk = 2.6%), 14 of 201 current
users of SSRI underwent a re-operation [risk = 7.0%,
risk difference = 4.3% (95% CI 0.8%, 7.9%), risk ratio =
2.7 (95% CI 1.6, 4.4)], and 37 of 1391 former users of
SSRI underwent a re-operation [risk = 2.7%, risk differ-
ence = 0.03% (95% CI -0.9%, 0.9%), risk ratio = 1.0 (95%
CI 0.72, 1.4)].
The elevated risk of re-operation among current users of
SSRI remained after adjustment for age (aRR = 2.3, 95%CI
1.4, 3.9) when compared with never users. Similarly, the
near-null association between former use of SSRIs and re-
operation due to post-surgical bleeding remained after
adjustment for age (aRR = 0.93, 95%CI 0.66, 1.3). Further
adjustment for other medications or the selected potential
confounding comorbid diseases did not substantially affect
the risk ratio estimates of association.
Discussion
We hypothesized that current use of SSRI would
increase the risk of re-operation after breast cancer sur-
gery due to postoperative bleeding, and the results of
this investigation were consistent with that hypothesis.
While current users of SSRI had almost tripled the risk
of re-operation due to postoperative bleeding, the abso-
lute change in risk was only from 2.7% to 7.0%.
The present study is population-based with complete
prescription and follow-up data. Recall-bias was elimi-
nated by use of prescription records generated before
the initial breast cancer surgery date and all data were
obtained prospectively from population-based registries
that have a completeness approaching 100% [15]. This
information was linked together by the unique CPR
number [9] that has been used productively for
research housed in the Danish registries for 15 years
[16,17].
Our comparison of post-surgical bleeding risk in SSRI
users versus never SSRI users may raise a concern about
non-comparability of the baseline risk of post-surgical
bleeding related to indications for SSRI use. For exam-
ple, patients with a history of depression, which is the
primary indication for SSRI use, may tend to have a less
healthy lifestyle than patients without a history of
depression with respect to tobacco use, diet, alcohol use,
and exercise [18,19]. Depressed patients may also more
often use pain medications, such as NSAID, which are
known to impair platelet aggregation and thus increase
risk of bleeding. This non-comparability of baseline risks
would lead to an overestimation of the effect of SSRI
use on the risk of re-operation. We controlled con-
founding by the most frequently used drugs and comor-
bid diseases related to coagulation and bleeding, and
this control had little impact on the estimates of asso-
ciation. However, we were unable to control for NSAIDs
bought over the counter or alcohol consumption, as we
have no reliable registry data on these habits.
A limitation of the current study is that it includes no
information on SSRI prescription compliance. For exam-
ple, women defined as current users may not have taken
the medication up to the day of surgery. Our informa-
tion on SSRI use relied on registration of dispensed pre-
scriptions and the Danish health care system covers
only a proportion of the costs of prescribed medicine.
Dispensed prescriptions for which patients must pay
part of the cost are likely to be actually used. Further-
more, women on anti-depressant medication with the
additional distress of a newly diagnosed breast cancer
w o u l db eu n l i k e l yt os t o pt h e ir anti-depressant medica-
tion. Earlier studies on orthopaedic surgery and coron-
ary artery bypass surgery [5,6], have used the
requirement of blood transfusion as a proxy for peri-
operative bleeding when investigating its association
with SSRI use. We used re-operation due to post surgi-
cal bleeding, because peri-operative bleeding in the case
of breast cancer surgery rarely results in blood transfu-
sion. In addition, registration of re-operation due to
post surgical bleeding in the Danish National Registry of
Patients is virtually complete [20-22].
The overall risk of re-operation due to postoperative
bleeding in breast cancer patients observed in our study
was of the same magnitude as that observed in a small
single centre cohort (0.8-4.1%) [7], which adds further
support to the validity of our outcome measure.
Gärtner et al. BMC Surgery 2010, 10:3
http://www.biomedcentral.com/1471-2482/10/3
Page 3 of 6Table 1 Characteristics of 14,464 breast cancer patients
# according to SSRI prescription.







<40 2010 (16) 147 (9) 2157 (15)
40-49 2669 (21) 311 (20) 2980 (21)
50-59 3117 (24) 373 (23) 3490 (24)
60-69 2441 (19) 313 (20) 2754 (19)
70-79 1699 (13) 258 (16) 1957 (14)
>=8 0 936 (7) 190 (12) 1126 (8)
Temporality of Anti-depressant (including SSRI, TCA, TeCA, others)
Prescription
Never 11857 (92) 0 11857 (82)
Current 266 (2) 411 (26) 677 (5)
Former 749 (6) 1181 (74) 1930 (13)
Primary operation type
Breast-conserving surgery 7799 (61) 936 (59) 8735 (60)
Mastectomy 5073 (39) 656 (41) 5719 (40)
Anti-depressant prescription
Never 11857 (92) 0 11857 (82)
SSRI 0 1592 (100) 1592 (11)
Tricyclic anti-depressants 526 (4) 0 526 (4)
Tetracyclic anti-depressants 131 (1) 0 131 (1)
Other 358 (3) 0 358 (3)
Oral Anti-coagulants prescription
No 12860 (99.9) 1589 (99.8) 14449 (99.9)
Yes 12 (0.1) 3 (0.2) 15 (<0.1)
NSAIDs prescription
No 6134 (48) 493 (31) 6627 (46)
Yes 6738 (52) 1099 (69) 7837 (54)
Aspirin prescription
No 12164 (95) 1423 (89) 13587 (94)
Yes 708 (6) 169 (11) 877 (6)
Corticosteroid prescription
No 10969 (85) 1194 (75) 12163 (84)
Yes 1903 (15) 398 (25) 2301 (16)
Vitamin K Antagonists Prescription
No 12599 (98) 1529 (96) 14128 (98)
Yes 273 (2) 63 (4) 336 (2)
Platelet Inhibitors Prescription
None 11924 (93) 1341 (84) 13265 (92)
Yes 948 (7) 251 (16) 1199 (8)
Comorbid diseases*
None 11764 (91) 1396 (88) 13160 (91)
Yes 1108 (9) 196 (12) 1304 (9)
Comorbid Diseases
Liver disease 72 (0.6) 23 (1.4) 95 (0.7)
Renal disease 89 (0.7) 27 (2) 116 (0.8)
Cancer 951 (7) 141 (9) 1092 (8)
Thrombocytopoenia 7 (0.05) 1 (0.06) 8 (0.06)
Auto-immune disease 3 (0.02) 3 (0.02) 6 (0.04)
Vascular disease 12 (0.1) 3 (0.2) 15 (<1)
#Women diagnosed in Northern Denmark between 1996 and 2007 with complete prescription coverage since 1999.
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has been discussed for almost two decades [1,2,23].
Breast cancer surgery is a soft tissue surface-surgery
often characterised by extensive dissection, which
increases the risk of postoperative bleeding compared
with many other surgical soft tissue procedures. As we
found an increased risk of re-operation due to post-sur-
gical bleeding associated with current use of SSRI, our
findings may also be relevant to other soft-tissue surgi-
cal procedures of similar character where bleeding
might have more fatal consequences.
Our results show overall low risk of re-operation due
to post-surgical bleeding among breast cancer patients
regardless of whether they are current, former, or never
users of SSRI medications. The consequence of stopping
SSRI medication used to treat depression in women
undergoing treatment for breast cancer may be over-
whelming, and may even delay any subsequent cancer-
directed treatment. Thus, the potential consequences of
stopping the treatment – taken together with the low
overall risk – suggests that physicians and patients
should discuss the risks and benefits of discontinuing
treatment with SSRI before breast cancer surgery.
Conclusion
Use of SSRI is associated with an increased risk of re-
operation due to bleeding after surgery for breast can-
cer, from about 3% to about 7%. However, the magni-
tude of the risk difference does not merit pausing
antidepressive medicine in psychologically vulnerable
patients without a complete discussion of the risks and
benefits.
APPENDIX
ATC codes for potential confounding drugs:
Platelet inhibitors: (low-dose aspirin B01AC06 and
N02BA01 in tablet sizes of 75, 100 or 150 mg;
Vitamin K antagonists: (heparin B01AB01; warfarin
B01AA03; phenprocoumon B01AA04), dipyridamol
B01AC07; clopidogrel B01AC04);
Oral anti-coagulants: (B01AB02, B01AB04, B01AB05,
B01AB08, B01AB10, B01AC06, B01AC09, B01AC13,
B01AC14, B01AC16, B01AC17, B01AC30, B01AD01,
B01AD02, B01AD04, B01AD07, B01AD10, B01AD11,
B01AE04, B01AE05, B01AX03, B01AX05);
NSAIDs: (non-aspirin NSAIDs M01A*, excluding
selective Cox-2 inhibitors);
Anti-depressants: Tri-cyclic anti-depressants (TCAs):
Desipramine N06AA01; imipramin N06AA02; imipra-
mine oxide N06AA03; clomipramin N06AA04; opipra-
mol N06AA05; trimipramine N06AA06; lofepramine
N06AA07; amitriptylin N06AA09; nortriptylin
N06AA10; protriptyline N06AA11; doxepin N06AA12;
dosulepin N06AA16; amoxapine N06AA17; Tetracyclical
anti-depressants (TeCA): Maprotilin N06AA21, Mian-
serin N06AX03; Other anti-depressants: Duloxetin
N06AX21, venlafaxin N06AX16, Mirtazapin N06AX11,
Reboxetin N06AX18, Isocarboxazid N06AF01, Moclobe-
mid N06AG02.
Abbreviations
(SSRI): Selective serotonin reuptake inhibitors; (CPR): Civil Personal
Registration; (ICD): International Statistical Classification of Diseases and
Related Health Problems; (NSAIDs): non-steroidal anti-inflammatory drugs;
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Table 2 Risk of re-operation due to post-surgical bleeding after breast cancer surgery according to SSRI prescription
among 14,464 women
#.
Re-operation/Cohort members Risk (%) Crude RR (95%CI) Adjusted RR* (95%CI)
SSRI Prescription
Never 338/12872 2.6 1.0 1.0
Ever 51/1592 3.2 1.2 (0.91, 1.7) 1.1(0.83, 1.5)
Temporality^ of SSRI prescription
Never 338/12872 2.6 1.0 1.0
Current 14/201 7.0 2.7 (1.6, 4.4) 2.3 (1.4, 3.9)
Former 37/1391 2.7 1.0 (0.72, 1.4) 0.93 (0.66, 1.3)
Risk of re-operation occurring in the first fourteen days after surgery was estimated in never, ever, current and former users.
Current users were defined as women with a prescription of SSRI within 30 days before initial breast cancer surgery.
Former users were defined as women with a prescription of SSRI more than 30 days before initial breast cancer surgery.
# Women diagnosed in Northern Denmark between 1996 and 2007 with complete prescription coverage since 1999.
^Temporality of current use of SSRI was defined as prescriptions within 30 days prior to admission for surgery.
*Adjusted for age
SSRI = Selective serotonin reuptake inhibitors, RR = risk ratio, CI = 95% confidence interval
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